Tag: wuxi-pharma-tech

Reading Time: 2 minutes WuXi Pharma Tech (NYSE:WX) continued to slide, during my absence. One (main) concern is heavy insider selling (source: seekingalpha) lately, after the secondary offering was suspended on May 4. I double checked the F1 filings for secondary offering (principal and selling shareholders), and found its CEO Dr. Ge Li was going to sell 8 million

June 19, 2008

Reading Time: < 1 minute I bought some Wuxi Pharma (NYSE:WX) shares today, last year I traded it shortly after its IPO in Aug/Sept. Recent developments Q4 and full year 2007 results (MSN Money): total net revenues increased 93.3% to $135.2 million (compared to 2006); Chemsitry CRO of the year by Pfizer; Q1 2008 results to be released on May

May 6, 2008

Reading Time: < 1 minute Here are the results from Yahoo Finance, some highlights: Second Quarter 2007 Highlights: — Total net revenues increased 99.3% over the second quarter of 2006 to US$30.2 million. (1H revenue $64 m, slight decline over Q1 2007?) — Net income increased 482.1% over the second quarter of 2006 to US$7.1 million. — Diluted earnings per

September 9, 2007

Reading Time: 2 minutes WuXi Pharma Tech (NYSE: WX) is a pharmaceutical R&D service company based in Shanghai, and they do work for the pharma giants like Pfizer, Merck, etc. They are the No. 1 player in China and growing fast. To give some background, here is a discussion thread from trader168.com; and a valuation analysis article from Yahoo

August 12, 2007
Follow Us
Google Ads
Recent Comments
Recent Posts